Medical Education Library

Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults

Publish date: June 19, 2018
This supplement is sponsored by Salix Pharmaceuticals.

 

Click to read supplement.

In this supplement to Internal Medicine News , Christine Frissora, MD provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined.

Topics include:

  • IBS-D diagnosis and treatment challenges

  • The role of microbial imbalance and altered gut microbiota

  • A treatment option for relief of IBS-D symptoms

Click to read supplement.

XIFI.0273.USA.18

Recommended Reading

Barrett’s segment length, low-grade dysplasia tied to increased risk of neoplastic progression
MDedge Internal Medicine
ACS: Start colorectal cancer screening at age 45
MDedge Internal Medicine
Bezafibrate shows promise as second-line option for PBC
MDedge Internal Medicine
Web portal does not reduce phone encounters or office visits for IBD patients
MDedge Internal Medicine
Shingles hospitalization occurs more often among IBD patients
MDedge Internal Medicine
Malnourished U.S. inpatients often go untreated
MDedge Internal Medicine
Tenapanor shows safety, efficacy for irritable bowel syndrome
MDedge Internal Medicine
Insurer denials of DAA therapy for HCV on the rise
MDedge Internal Medicine
Fundoplication works best for true PPI-refractory heartburn
MDedge Internal Medicine
Magnetic LES augmentation for Barrett’s regression debated
MDedge Internal Medicine